Literature DB >> 27620495

Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination.

Rudruidee Karnchanasorn1, Horng-Yih Ou2, James Lin3, Lee-Ming Chuang4,5, Ken C Chiu6,7.   

Abstract

Viral hepatitis has been posited to play a role in the development of type 2 diabetes. Thus, prevention of viral hepatitis through vaccination has the potential to reduce the burden of type 2 diabetes. We have shown that successful hepatitis B vaccination reduces the risk of diabetes by 33 %. Although diabetes can be prevented by behavior modification and pharmaceutical agents, these require significant personal commitment and cost. In contrast, diabetes prevention through hepatitis B vaccination would require little personal commitment and relatively low cost. In this review, we discuss hepatitis viruses A, B, and C and their interaction with diabetes; explore the potential underlying mechanisms and potential for hepatitis vaccination to reduce diabetes; and estimate the medical expense savings that would result from such an intervention. Given the projected increase of diabetes prevalence in the developing regions, where hepatitis B is endemic, exploration of such an intervention is very timely.

Entities:  

Keywords:  Diabetes mellitus; Diabetes prevention; Hepatitis; Liver; Vaccination

Mesh:

Substances:

Year:  2016        PMID: 27620495     DOI: 10.1007/s11892-016-0790-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  76 in total

Review 1.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

Authors:  A D Cherrington
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

2.  First-pass hepatic extraction and metabolic effects of insulin and insulin analogues.

Authors:  Z Chap; T Ishida; J Chou; C J Hartley; M L Entman; D Brandenburg; R H Jones; J B Field
Journal:  Am J Physiol       Date:  1987-02

Review 3.  Diabetes and liver disease: an ominous association.

Authors:  Simona Moscatiello; Rita Manini; Giulio Marchesini
Journal:  Nutr Metab Cardiovasc Dis       Date:  2007-01       Impact factor: 4.222

4.  Hepatitis B virus infection status and risk of type 2 diabetes mellitus: A meta-analysis.

Authors:  Jian Zhang; Yi Shen; Hui Cai; Yan-Mei Liu; Gang Qin
Journal:  Hepatol Res       Date:  2015-02-15       Impact factor: 4.288

5.  Association of insulin resistance with serum ferritin and aminotransferases-iron hypothesis.

Authors:  Jean Huang; Rudruidee Karnchanasorn; Horng-Yih Ou; Wei Feng; Lee-Ming Chuang; Ken C Chiu; Raynald Samoa
Journal:  World J Exp Med       Date:  2015-11-20

6.  Diabetes mellitus associated with epidemic of infectious hepatitis in Nigeria.

Authors:  F C Adi
Journal:  Br Med J       Date:  1974-02-02

7.  Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication.

Authors:  Jee-Fu Huang; Chia-Yen Dai; Shang-Jyh Hwang; Chi-Kung Ho; Pi-Jung Hsiao; Ming-Yen Hsieh; Li-Po Lee; Zu-Yau Lin; Shinn-Chern Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Shyi-Jang Shin; Wen-Yu Chang; Wan-Long Chuang; Ming-Lung Yu
Journal:  Am J Gastroenterol       Date:  2007-06       Impact factor: 10.864

Review 8.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2015-06-07       Impact factor: 202.731

9.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Authors:  Graham R Foster; Nezam Afdhal; Stuart K Roberts; Norbert Bräu; Edward J Gane; Stephen Pianko; Eric Lawitz; Alex Thompson; Mitchell L Shiffman; Curtis Cooper; William J Towner; Brian Conway; Peter Ruane; Marc Bourlière; Tarik Asselah; Thomas Berg; Stefan Zeuzem; William Rosenberg; Kosh Agarwal; Catherine A M Stedman; Hongmei Mo; Hadas Dvory-Sobol; Lingling Han; Jing Wang; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Francesco Mazzotta; Tram T Tran; Stuart C Gordon; Keyur Patel; Nancy Reau; Alessandra Mangia; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-11-17       Impact factor: 91.245

10.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.